Rossari Biotech Ltd
NSE:ROSSARI
Rossari Biotech Ltd
Rossari Biotech Ltd. operates as a specialty chemicals manufacturing company. The company is headquartered in Mumbai, Maharashtra and currently employs 451 full-time employees. The company went IPO on 2020-07-23. The firm provides customized solutions to industrial and production requirements of its customers through its diversified product portfolio. The company builds its expertise from textiles and has diversified into the animal health and nutrition, home, personal care and performance chemicals markets. The company offers a range of sustainable products for pre-treatment, dyeing, printing, finishing processes, and specialty chemicals. The firm provides specialty chemical solutions across the entire value-chain of the textile industry starting from thread, yarn and man-made fiber production to digital printing, fabric processing, dyeing auxiliaries and garment finishing range. The company develops product portfolio for its businesses of home, personal care and performance chemicals. The firm operates two manufacturing facilities at Silvassa and Dahej.
Rossari Biotech Ltd. operates as a specialty chemicals manufacturing company. The company is headquartered in Mumbai, Maharashtra and currently employs 451 full-time employees. The company went IPO on 2020-07-23. The firm provides customized solutions to industrial and production requirements of its customers through its diversified product portfolio. The company builds its expertise from textiles and has diversified into the animal health and nutrition, home, personal care and performance chemicals markets. The company offers a range of sustainable products for pre-treatment, dyeing, printing, finishing processes, and specialty chemicals. The firm provides specialty chemical solutions across the entire value-chain of the textile industry starting from thread, yarn and man-made fiber production to digital printing, fabric processing, dyeing auxiliaries and garment finishing range. The company develops product portfolio for its businesses of home, personal care and performance chemicals. The firm operates two manufacturing facilities at Silvassa and Dahej.
Revenue Growth: Rossari Biotech delivered 13% year-on-year revenue growth in Q3 FY '26, reaching INR 581.7 crores, despite muted domestic demand.
Profitability Pressures: EBITDA margin declined to 11.8%, with margins impacted by investments in capacity expansion, product development, and higher employee costs.
Segment Performance: All business segments grew year-on-year; Textile Specialty Chemicals up 18%, HPPC up 11%, and Animal Health & Nutrition up 39%.
Exports Strong: Exports grew 26% in the first 9 months, now accounting for 33% of Q3 revenue and 30% year-to-date.
Capacity Ramp-Up: New 15,000 MT ethoxylation facility at Unitop is ramping up, currently at 10–15% utilization, with optimal utilization expected by FY '27.
International Expansion: Board gave in-principle approval for a greenfield facility in Saudi Arabia to enhance supply chain resilience and global reach.
B2C Challenges: Institutional and B2C businesses remain subdued, with management considering strategic changes, including possibly selling the consumer segment to improve margins.
Margin Outlook: Management expects EBITDA margin to stay around 12–13% until EO supply improves, but sees a path back to 15% with product mix improvements and potential B2C divestment.
